Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of MK-1045 versus blinatumomab in relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia
MOH_2026-03-26_015735Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of CN201 and blinatumomab in B cell acute lymphoblastic leukemia (B-ALL) and acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Merck & Co. Primary endpoints: Safety of MK-1045, Efficacy of MK-1045 and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
CN201blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on MOH_2026-03-26_015735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-26_015735.